IMPORTANCE Nausea and vomiting affects approximately 85% of pregnant women. The most severe form, hyperemesis gravidarum, affects up to 3% of women and can have significant adverse physical and psychological sequelae.
Both fixed-or random-effects model meta-analysis and a Bayesian mixed treatment comparison were planned as stipulated in the protocol (PROSPERO CRD42013006642) but were not performed because of heterogeneity in interventions, trial populations, reporting, and definitions of outcome measures and methods. Data were therefore summarized narratively and prioritized to emphasize the highest quality of evidence, defined as randomized clinical trials with a low risk of bias.
Results
The search identified 13 075 titles, of which 222 underwent full review. Seventy-eight studies (n = 8930 participants) met our inclusion criteria (see eFigure in the Supplement). Of these, 11 RCTs were classified as having high within-study risk of bias, mainly attributable to allocation concealment bias, lack of blinding, incomplete outcome data, or selective outcome reporting. Twenty-one were classified as being at unclear risk of bias, mainly because of poor reporting and lack of methodological detail. The quality of case series and nonrandomized studies was weak (n = 9) or moderate (n = 2). The remaining 35 RCTs 18-52 were at low risk of bias and are presented below and summarized in eTables 1-3 in the Supplement (details for all other included studies are summarized in eTables 4-6 in the Supplement). Evidence grades and recommendations are reported in Table 2 .
Treatment
Treatment focuses on relieving symptoms and preventing serious morbidity such as Wernicke encephalopathy, renal impairment, and extreme weight loss. [53] [54] [55] Treatments can be categorized into 3 broad yet overlapping groups. First-line treatments, including simple lifestyle changes (such as eating small amounts often, avoiding dietary triggers and strong odors, eating high-carbohydrate, low-fat foods) and over-the-counter remedies, such as vitamin B 6 (pyridoxine), ginger, and sea bands (an acupressure towelling wrist band that stimulates the Pericardium P6 acupressure point), are usually initiated by women when first experiencing symptoms. Second-line treatments are typically prescribed when a woman first presents to medical care, usually by her obstetric care provider, and include a range of antiemetic drugs as well as provision of intravenous fluid and electrolyte replacement for women who are dehydrated and ketotic. Third-line treatments are reserved for women with severe, persistent symptoms and are initiated in a hospital setting. These include corticosteroids and supportive therapy, such as enteral feeding. Depending on symptom severity, women may progress from one category to another or may bypass first-line treatments. When second-or third-line treatments fail, some women opt for termination of pregnancy. 56 (a complex score designed by the authors that takes into account intensity of nausea, vomiting, weight loss, ketonuria, and hematocrit; range not provided), improved more for ginger compared with placebo over two 5-day treatment periods (4.1 vs −0.1 and 3.7 vs 0.9 [P = .035]). Vutyavanich et al 20 (n = 70) reported a greater improvement in VAS scores for nausea (2.1 v 0.9, P = .014) and vomiting episodes (1.4 v 0, P < .001) in the ginger group compared with placebo. Similarly, Keating and Chez 21 (n = 26) reported greater improvements in VAS scores for nausea (10 women in the ginger group had greater than a 4-point improvement compared with 2 women in the placebo group by day 9), and a greater proportion stopped vomiting in the ginger group (8 women in the ginger group compared with 2 in the placebo group by day 6, P value not reported). Four RCTs compared ginger capsules and vitamin B 6 .
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Chittumma et al (n = 126) 22 In summary, treatment with vitamin B 6 was associated with symptom improvement for mild cases (level A, class IIa). In summary, treatment with vitamin B 6 (pyridoxine)-doxylamine was associated with symptom improvement for women with mild-moderate symptoms (level A, class IIa).
Erez et al 41 (n = 150) compared hydroxyzine hydrochloride (25 mg twice daily for 3 weeks) with placebo. Symptom improvement occurred in the treatment group with partial or complete relief of symptoms in 82% of women, compared with only 22% in the placebo group (P < .01). In summary, limited-quality evidence indicated that treatment with antihistamines was associated with symptom improvement in mild-moderate cases (level B, class IIa). 3] , respectively [P = .013]). The ondansetron group had lower vomiting scores than the metoclopramide group calculated over 14 days (P = .042, raw data not provided), but there was no difference in trend in nausea scores over 14 days between groups. In summary, treatment with serotonin receptor antagonists was associated with improvement in symptoms of all severities (level A, class IIa).
Intravenous Fluids | Tan et al 46 (n = 222) compared different compositions of intravenous solution. The intervention group received intravenous dextrose saline with antiemetics according to health care provider preference, whereas the comparator group received normal saline with antiemetics. Repeated-measures analysis of variance of nausea score found greater improvements in the dextrose saline group relative to the saline group (P = .046), but no difference in vomiting was reported. In summary, limited evidence indicated that dextrose saline may be associated with better improvements than normal saline in moderate-severe cases (level B, class IIa). In summary, evidence indicated that outpatient treatment was associated with benefits that are not better or worse than inpatient intravenous therapy in patients with moderate symptoms (level A, class IIa). methazine. There was no difference in symptom improvement by 1 week. However, no patients from the methylprednisolone group were readmitted for recurrence of vomiting, compared with 5 patients from the promethazine group (P < .01).
Bondok et al 51 (n = 40) compared hydrocortisone with metoclopramide. Steroids were associated with a greater reduction in vomiting episodes compared with metoclopramide (emesis reduction, 40.9% vs 16.5% at day 2; 71.6% vs 51.2% at day 3; 95.8% vs 76.6% at day 7 [n = 40, P < .001]). In summary, evidence indicated that benefits of corticosteroids were unclear. Treatment may be considered in severe cases (level A, class IIb)
Transdermal Clonidine | Transdermal clonidine patches were investigated in 1 randomized crossover trial by Maina et al 52 (n = 12) in patients unresponsive to other antiemetics. Either clonidine or placebo patches were worn for 5 days before the treatment was alternated. Intravenous fluids and rescue antiemetics were given as required. The mean improvement in symptom scores was greater for clonidine treatment (mean PUQE score, 6.3 [95% CI, 5.5-7.1] for clonidine and 8.5 [95% CI, 7.7-9.3] for placebo, P = .001), and there was less use of antiemetics and intravenous therapy in the clonidine group. In summary, limited evidence indicated treatment with transdermal clonidine was associated with symptom improvements, but currently this is not an established treatment for nausea and vomiting in pregnancy in clinical practice (level B, class IIb). 
Discussion
The review found low-quality evidence for therapies treating nausea and vomiting in pregnancy and hyperemesis gravidarum. Less than half of all studies were judged as being at low risk of bias. Ginger, acupressure, and vitamin B 6 are appropriate initial overthe-counter therapies for mild symptoms. Treatment with nerve stimulation may be considered, but, as with acupuncture, the benefit is unclear.
When symptoms are mild-moderate, or if the above over-thecounter therapies were not beneficial, antihistamines (alone or combined with vitamin B 6 ) were associated with improved symptoms compared with placebo. Limited evidence indicated an association between psychotherapy, metoclopramide, and promethazine and improvements in moderate symptoms. There was no evidence to indicate that these treatments are unsafe, but more research is needed.
When symptoms are moderate-severe, outpatient, day-care management is feasible, acceptable, and does not result in worse outcomes compared with inpatient care. The serotonin receptor antagonist ondansetron improves symptoms at all severities, but benefit compared with metoclopramide or antihistamines is unclear. Ondansetron appears to be safe in pregnancy, 59 but evidence is limited and more research is needed. Large doses of intravenous ondansetron (more than 8 mg in 1 intravenous dose) are contraindicated in women at risk of cardiac arrhythmias (QT prolongation). In such circumstances, an electrocardiogram should be performed and electrolyte levels checked prior to treatment. 60 There is no evidence that oral administration of ondansetron causes QT prolongation in adults.
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When symptoms are more severe or persistent, corticosteroids are associated with improved symptom severity and may be more beneficial than metoclopramide and promethazine. However, use is generally limited to women with severe intractable symptoms with prior treatment failure, preferably after 10 weeks' gestation and during an inpatient admission. This arises from concerns regarding a small increase in incident oral clefts in fetuses exposed to corticosteroids in utero in pooled data from observational studies. 61 More evidence is needed comparing corticosteroids with other medications.
Comparison With Previous Literature
The American College of Obstetricians and Gynecologists published clinical management guidelines in August 2015, 2 recommending the use of vitamin B 6 or vitamin B 6 plus doxylamine as first-line pharmacotherapy, ginger as a nonpharmacological option, and methylprednisolone in refractory cases. Recommendations based on consensus include intravenous hydration and enteral tube feeding for women who are not responsive to medical therapy. Many of the findings in this review support recommendations in the guidelines. However, although pyridoxine plus doxylamine was more effective than placebo, there is no substantial evidence to suggest that the combination is more effective than other antiemetics such as antihistamines. Moreover, this review adds value by categorizing therapies depending on symptom severity. Two Cochrane reviews were published recently. 62, 63 Matthews et al 62 included only RCTs focusing on nausea and vomiting and excluded trials involving hyperemesis gravidarum; the review by Boelig et al 63 only included RCTs of hyperemesis gravidarum. Neither review categorized therapies depending on symptom severity. However, both reviews were consistent in concluding that there is little good-quality evidence to support any available intervention.
Limitations
These recommendations are limited by the quality and heterogeneity of evidence. Quality was downgraded due to clinical heterogeneity, imprecision, sparseness of data, or a combination of these factors. There was also considerable variation in the initial assessment and subsequent reporting of nausea, vomiting, and other relevant outcomes in the identified studies. As a result, we were unable to conduct the planned meta-analysis stipulated in our original protocol. One set of outcome measures likely to be important to women and practitioners is safety. We sought to assemble data on fetal outcomes and adverse events; however, no reliable safety data were identified in the included studies. Details of common adverse effects of the interventions recommended by this review are provided in Table 3 , along with common dosage regimens. Available observational data (pregnancy-related but not specifically focused on nausea and vomiting) does not provide evidence of any safety concerns with antiemetic medications; this is not the same as ruling out any important differences in adverse outcomes.
Conclusions
For mild symptoms of emesis and nausea of pregnancy, ginger, pyridoxine, antihistamines, and metoclopramide were associated with greater benefit than placebo. For moderate symptoms, pyridoxinedoxylamine, promethazine, and metoclopramide were associated with greater benefit than placebo. Ondansetron was associated with symptom improvement for a range of symptom severity. Corticosteroids may be associated with benefit in severe cases. Overall, the quality of evidence was low. 
